1. In this randomized controlled trial, among patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis, resmetirom was superior to placebo in improving fibrosis. 2. Diarrhea and nausea were the most common adverse events associated with resmetirom. Evidence Rating Level: 1 (Excellent) Study Rundown: NASH is a progressive liver disease associated with metabolic dysfunction characterized by